Equillium, Inc. (0A4D.L)
| Previous close | 1.7000 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 2,796 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., April 03, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee appr
- Business Wire
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
LA JOLLA, Calif., April 01, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from the Type B portion of the Phase 1b EQUALISE study evaluating itolizumab in lupus nephritis patients. The data suggests high complete and partial response rates with rapid and deep reduction in urine protein creatinine ratio (UPCR) when itolizumab was added t
- Business Wire
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
LA JOLLA, Calif., March 25, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights.
